Literature DB >> 19141381

Neuroendocrine carcinomas of the lung: a critical analysis.

Cesar A Moran1, Saul Suster, Domenico Coppola, Mark R Wick.   

Abstract

Neuroendocrine carcinomas represent an important group of primary neoplasms in the lung. During the last decades, the nomenclature of these tumors has evolved and the current use of immunohistochemical and molecular biology studies have, to some extent, expanded the conventional view of these tumors. However, the primary diagnosis of most of these lesions is performed on limited biopsy specimens, which may not translate well when one is confronted with a nomenclature that is based on resected material. In addition, for some of these specific entities, some confusion and controversy apparently remain, allowing for the proliferations of different terms that, although they may be dismissed as "semantics," may have a role in interpretation, further subclassification, and, possibly, treatment. Herein we review current concepts regarding the classification of these neoplasms and the role of this classification in our daily practice and discuss how it may impact treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141381     DOI: 10.1309/AJCP9H1OTMUCSKQW

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

Review 1.  Therapeutic biomarkers in lung neuroendocrine neoplasia.

Authors:  Luisella Righi; Marco Volante; Ida Rapa; Simona Vatrano; Giuseppe Pelosi; Mauro Papotti
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

Review 2.  Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.

Authors:  Talal Hilal
Journal:  Ther Adv Med Oncol       Date:  2016-11-17       Impact factor: 8.168

3.  Pulmonary neuroendocrine carcinomas-evidence for a spectrum of differentiation.

Authors:  Annikka Weissferdt
Journal:  Virchows Arch       Date:  2018-01-31       Impact factor: 4.064

4.  Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

Authors:  Matthew H Kulke; Lillian L Siu; Joel E Tepper; George Fisher; Deborah Jaffe; Daniel G Haller; Lee M Ellis; Jacqueline K Benedetti; Emily K Bergsland; Timothy J Hobday; Eric Van Cutsem; James Pingpank; Kjell Oberg; Steven J Cohen; Mitchell C Posner; James C Yao
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

5.  Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.

Authors:  Alessandra Fabbri; Mara Cossa; Angelica Sonzogni; Mauro Papotti; Luisella Righi; Gaia Gatti; Patrick Maisonneuve; Barbara Valeri; Ugo Pastorino; Giuseppe Pelosi
Journal:  Virchows Arch       Date:  2017-01-04       Impact factor: 4.064

6.  Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry.

Authors:  Adele Caldarella; Emanuele Crocetti; Eugenio Paci
Journal:  Pathol Oncol Res       Date:  2011-04-09       Impact factor: 3.201

Review 7.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

8.  Molecular challenges of neuroendocrine tumors.

Authors:  Parthik Patel; Karina Galoian
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

9.  Long-term management of a patient with well-differentiated pulmonary neuroendocrine carcinoma: a case report.

Authors:  Thaddeus Beck; Ryan Mantooth
Journal:  Case Rep Oncol       Date:  2013-04-06

10.  Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.

Authors:  Tao Cui; Monica Hurtig; Graciela Elgue; Su-Chen Li; Giulia Veronesi; Ahmed Essaghir; Jean-Baptiste Demoulin; Giuseppe Pelosi; Mohammad Alimohammadi; Kjell Öberg; Valeria Giandomenico
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.